144 related articles for article (PubMed ID: 34160091)
21. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease.
Han JE; Yi SK; Wang S; Erman A; Bearelly S; Sindhu S; Robbins JR; Bauman J; Hsu CC
Head Neck; 2019 Dec; 41(12):4076-4087. PubMed ID: 31520512
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
Yang H; Liu Y; Zhang R; Ye Y; Chen Q; Qin Q; Huang L; Li X; Cai R; Tang H; Jiang W
Oral Oncol; 2020 Nov; 110():104897. PubMed ID: 32679404
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
[TBL] [Abstract][Full Text] [Related]
26. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
[TBL] [Abstract][Full Text] [Related]
28. The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database.
Ahmed Z; Kujtan L; Kennedy K; Wood V; Schomas D; Subramanian J
Cancer Med; 2019 Apr; 8(4):1500-1507. PubMed ID: 30790468
[TBL] [Abstract][Full Text] [Related]
29. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
Zang J; Li C; Xu M; Xu W; Kang X; Wang J; Luo S; Shi M
Sci Rep; 2018 Sep; 8(1):13318. PubMed ID: 30190563
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a magnetic resonance imaging-based model for the prediction of distant metastasis before initial treatment of nasopharyngeal carcinoma: A retrospective cohort study.
Zhang L; Dong D; Li H; Tian J; Ouyang F; Mo X; Zhang B; Luo X; Lian Z; Pei S; Dong Y; Huang W; Liang C; Liu J; Zhang S
EBioMedicine; 2019 Feb; 40():327-335. PubMed ID: 30642750
[TBL] [Abstract][Full Text] [Related]
31. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia: A Retrospective Study.
Dwijayanti F; Prabawa A; Besral ; Herawati C
Oncology; 2020; 98(3):154-160. PubMed ID: 31995803
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and survival outcomes of ascending, descending and mixed types of nasopharyngeal carcinoma in the non-endemic areas of china: A propensity score matching analysis.
Fan Y; Guan W; Huang R; Lin SY; Song Y; Lu S; Kang L; Yang Q; Lang J; Zhang P
Cancer Med; 2020 Dec; 9(24):9315-9325. PubMed ID: 33058559
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
[TBL] [Abstract][Full Text] [Related]
34. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count.
Xie X; Gong S; Jin H; Yang P; Xu T; Cai Y; Guo C; Zhang R; Lou F; Yang W; Wang H
Radiat Oncol; 2020 Mar; 15(1):65. PubMed ID: 32169088
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
36. Receipt of Care Discordant with Practice Guidelines is Associated with Compromised Overall Survival in Nasopharyngeal Carcinoma.
Schwam ZG; Sosa JA; Roman S; Judson BL
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):402-9. PubMed ID: 26868285
[TBL] [Abstract][Full Text] [Related]
37. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
38. Survival impact of treatment-related time intervals in nasopharyngeal carcinoma in the United States.
Tham T; Ahn S; Teckie S; Roche A; Frank D; Kraus D; Costantino P
Laryngoscope; 2019 Nov; 129(11):2514-2520. PubMed ID: 30702156
[TBL] [Abstract][Full Text] [Related]
39. Basaloid nasopharyngeal carcinoma: A population-based analysis of a rare tumor.
Unsal AA; Booth JR; Rossi NA; Byrd JK; Kountakis SE
Laryngoscope; 2019 Dec; 129(12):2727-2732. PubMed ID: 30632158
[TBL] [Abstract][Full Text] [Related]
40. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy.
Alterio D; D'Ippolito E; Vischioni B; Fossati P; Gandini S; Bonora M; Ronchi S; Vitolo V; Mastella E; Magro G; Franco P; Ricardi U; Krengli M; Ivaldi G; Ferrari A; Fanetti G; Comi S; Tagliabue M; Verri E; Ricotti R; Ciardo D; Jereczek-Fossa BA; Valvo F; Orecchia R
Acta Oncol; 2020 May; 59(5):541-548. PubMed ID: 32090645
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
